Molecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor drug, C-1311

Biochemical Pharmacology

Volumn 66, Issue 9, 2003, Pages 1727-1736

  Mazerska, Zofia ^a   Sowiński, Pawel ^a   Konopa, Jerzy ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

C 1311; Imidazoacridinone antitumor agent; Mechanism of enzymatic activation; Metabolic activation; Peroxidase mediated activation; Products of enzymatic oxidation

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; HORSERADISH PEROXIDASE; HYDROGEN PEROXIDE; IMIDACRINE; MYELOPEROXIDASE;

ARTICLE; COVALENT BOND; DEALKYLATION; DNA BINDING; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE; OXIDATION; PRIORITY JOURNAL; SEPARATION TECHNIQUE; ULTRAVIOLET SPECTROSCOPY;

EID: 0141922902     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00477-5     Document Type: Article

References (38)

1. Cholody W.M., Martelli S., Lukowicz J., Konopa J. 5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. J. Med. Chem. 33:1990;49-52.
2. Cholody W.M., Martelli S., Konopa J. Chromophore-modified antineoplastic agents. Synthesis and activity against murine leukemias. J. Med. Chem. 35:1992;378-382.
3. Cholody W.M., Horowska B., Martelli S., Konopa J. Structure-activity relationship for antineoplastic imidazoacridinones: synthesis and antileukemic activity in vivo. J. Med. Chem. 39:1996;1028-1032.
4. Mazerska Z., Augustin E., Skladanowski A., Bibby M.C., Double J.A., Konopa J. C-1311 NSC-645809. Drugs Future. 23:1998;702-706.
5. Berger B., Marquardt H., Westendorf J. Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Cancer Res. 56:1996;2094-2104.
6. Burger A.M., Double J.A., Konopa J., Bibby M.C. Preclinical evaluation of novel imidazoacridone derivatives with potent activity against experimental colorectal cancer. Br. J. Cancer. 74:1996;1369-1374.
7. Burger A.M., Jenkins T.C., Double J.A., Bibby M.C. Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br. J. Cancer. 81:1999;367-375.
8. Calabrese C.R., Bibby M.C., Double J.A., Loadman P.M. Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour-bearing mice. Cancer Chemother. Pharmacol. 42:1998;379-385.
9. Skladanowski A., Plisov S.Y., Konopa J., Larsen K.L. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol. Pharmacol. 49:1996;772-780.
10. 2 phase of L1210 cells. Cancer Chemother. Pharmacol. 38:1996;39-44.
11. Augustin E., Konopa J. Imidazoacridinones induce apoptosis in murine leukemia L1210 cells. Folia Cytochem. Cytobiol. 34(Suppl. 2):1996;56.
12. 2M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines. Eur. J. Cancer. 37:2001;1953-1962.
13. Dziȩgielewski J., Ślusarski B., Konitz A., Skladanowski A., Konopa J. Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. Biochem. Pharmacol. 63:2002;1653-1662.
14. Mazerski J., Muchewicz K. The intercalation of imidazoacridinones into DNA induces conformational changes in their side chain. Acta Biochem. Polon. 47:2000;65-78.
15. Mazerska Z., Gorlewska K., Kraciuk A., Konopa J. The relevance of enzymatic oxidation by horseradish peroxidase to antitumor potency of imidazoacridinone derivatives. Chem. Biol. Interact. 115:1998;1-22.
16. Dziȩgielewski J., Konopa J. Interstrand crosslinking of DNA in tumor cells by a new group of antitumor imidazoacridinones. Proc. Am. Assoc. Cancer Res. 37:1996;410.
17. Dziȩgielewski J., Konopa J. Characterisation of covalent binding to DNA of antitumor imidazoacridone C-1311, after metabolic activation. Ann. Oncol. 9(Suppl. 1):1998;137.
18. Mazerska Z., Dziȩgielewski J., Konopa J. Enzymatic activation of a new antitumor drug, 5-diethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNA. Biochem. Pharmacol. 61:2001;685-694.
19. Mazerska Z, Klimkowska A, Adamczyk E, Konopa J. CYP2C and CYP3A are the principal enzymes involved in the in vitro metabolism of antitumor imidazoacridinone, C-1311. In: Proceedings of the 18th European Workshop on Drug Metabolism, Valencia, Spain, September 2002, Abstract 113.
20. Calabrese C.R., Loadman P.M., Lim L.S.E., Bibby M.C., Double J.A., Brown J.E., Lamb J.H. In vivo metabolism of the antitumor imidazoacridinine C1311 in the mouse and in vitro comparison with humans. Drug Metab. Dispos. 27:1998;240-245.
21. Klebanoff S.J. Phagocyte antimicrobial systems: myeloperoxidase. Proc. Assoc. Am. Phys. 111:1999;383-389.
22. Panousis C., Kettle A.J., Phillips D.R. Oxidative metabolism of mitoxantrone by the human neutrophil enzyme myeloperoxidase. Biochem. Pharmacol. 48:1994;2223-2230.
23. Kettle A.J., Robertson I.G.C., Palmer B.D., Anderson R.F., Patel K.B., Winterbourn C.C. Oxidative metabolism of amsacrine by the neutrophil enzyme myeloperoxidase. Biochem. Pharmacol. 44:1992;1731-1738.
24. Murao S., Stevens F.J., Ito A., Huberman E. Myeloperoxidase: a myeloid cell nuclear antigen with DNA-binding properties. Proc. Natl. Acad. Sci. U.S.A. 85:1988;1232-1236.
25. Guengerich F.P. Enzymatic oxidation of xenobiotic chemicals. Crit. Rev. Biochem. Mol. Biol. 25(2):1990;97-153.
26. O'Brien P.J. Peroxidases. Chem. Biol. Interact. 129:2000;113-139.
27. Hovorka S.W., Schöneich C. Oxidative degradation of pharmaceuticals. Theory, mechanism and inhibition. J. Pharm. Sci. 90:2001;253-269.
28. Meunier B, Auclair C, Bernadou J, Meunier G, Maftouh M, Cros S, Monsarrat B, Paoletti C. In vitro oxidative activation: a model for the cytotoxic action of 9-hydroxy ellipticine derivatives. In: Reinhoudt DN, Connors TA, Pinedo HM, van de Poll KW, editors. Structure-activity relationships of anti-tumour agents. Martinus Nijhoff Publisher; 1983. p. 151-81.
29. Maftouh M., Besselievre R., Monsarrat B., Lesca P., Meunier B., Husson H.P., Paoletti C. Synthesis and cytotoxic activity of hydroxylated derivatives of olivacine in relation with their biotransformation. J. Med. Chem. 28:1985;708-714.
30. Meunier G., De Montauzon D., Bernadou J., Grassy G., Bonnafous M., Cros S., Meunier B. The biooxidation of cytotoxic ellipticine derivatives: a key to structure-activity relationship studies? Mol. Pharmacol. 33:1987;93-102.
31. Renner U., Blanz J., Freund S., Waidelich D., Ehninger G., Zeller K.P. Biotransformation of CI-937 in primary cultures of rat hepatocytes. Drug Metab. Dispos. 23:1995;94-101.
32. Panousis C., Kettle A.J., Philips D.R. Myeloperoxidase oxidizes mitoxantrone to metabolites which bind covalently to DNA and RNA. Anticancer Drug Des. 10:1995;593-605.
33. Panousis C., Kettle A.J., Philips D.R. Neutrophil-mediated activation of mitoxantrone to metabolites which form adducts with DNA. Cancer Lett. 113:1997;173-178.
34. Parker B.S., Cullinane C., Philips D.R. Formation of DNA adducts by formaldehyde-activated mitoxantrone. Nucleic Acids Res. 27:1999;2918-2923.
35. Constantino L., Rosa E., Iley J. The microsomal demethylation of N,N-dimethylbenzamides. Substituent and kinetic deuterium isotope effects. Biochem. Pharmacol. 44:1992;651-658.
36. Chul-ho Y., Okerholm R.A., Guengerich F.P. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab. Dispos. 21:1993;403-409.
37. Mani C., Gelboin H.V., Park S.S., Pearce R., Parkinson A., Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. 1. Cytochrome P-450-catalysed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21:1993;645-656.
38. 2-methyl-9-hydroxyellipticinium to DNA in vitro. Biochemistry. 25:1986;1240-1245.